Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 8/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.50 |
| ▸ | GABRP | O00591 | 6/20 | 0.50 |
| ▸ | GABRD | O14764 | 6/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.50 |
| ▸ | GABRE | P78334 | 6/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26899199 | 0.86 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL17559377 | 0.84 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3110544 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1459953 | 0.83 | MAPK1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1425475 | 0.81 | GABRA1 (0.51) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20752332 | 0.80 | GABRA1 (0.51) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30937534 | 0.80 | MAPT (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL24665060 | 0.79 | HPGD (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29977825 | 0.79 | HPGD (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19231419 | 0.79 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-2925322-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9777002-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20150299198-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2925322-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299198-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | GABRA1 1325/4885GABRG2 2150/4885GABRB3 1781/4885 |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | GABRA1 2227/4885GABRG2 2705/4885GABRB3 3022/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | GABRA1 520/4885GABRG2 680/4885GABRB3 609/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | GABRA1 2137/4885GABRG2 2459/4885GABRB3 1840/4885 |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | REN, BDKRB2, BDKRB1 | GABRA1 172/4885GABRG2 383/4885GABRB3 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.